Under the terms of the agreement, Midwinter will distribute Sun’s portfolio of both injectable and solid dose drugs. Midwinter will become the sole point of contact for all clinical trial supply enquiries and orders for these products.
Included within Sun’s portfolio are the drugs Gemcitabine, Carboplatin and Temozolomide, all of which are experiencing increasing usage in clinical trials.
Midwinter Director Ben Everington commented;
“Sun Pharmaceutical’s portfolio of drugs, along with their desire to help provide important supplies to clinical trials, is perfectly suited to Midwinter’s core capabilities. With Midwinter’s global network of customers we aim to increase Sun Pharmaceuticals exposure to this important market place, as well as strengthening Midwinter’s ability to offer unparalleled solutions for clinical trial supply”
Sun Pharmaceuticals Head of UK Hospital Supply, Jim McCarthy commented;
“Midwinter have a great reputation in their field, we are glad to partner with a company that can offer a responsive and dedicated to service to Sun Pharmaceuticals, our customers and most importantly the end user”back